BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22502692)

  • 1. Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer.
    Turk HM; Camci C; Sevinc A; Bukyukberber S; Sari I; Adli M
    Asian Pac J Cancer Prev; 2012; 13(1):315-8. PubMed ID: 22502692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
    Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
    Shimizu K; Maeda A; Yukawa T; Nojima Y; Saisho S; Okita R; Nakata M
    World J Surg Oncol; 2014 Nov; 12():343. PubMed ID: 25392182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
    Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
    Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM
    Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Lung Cancer Mortality in a Referral Center.
    Jamaati H; Baghaei P; Sharifianfard M; Emami H; Najmi K; Seifi S; Salimi B; Pourabdollah M; Kiani A; Hashemian M; Khosravi A
    Asian Pac J Cancer Prev; 2016; 17(6):2877-81. PubMed ID: 27356706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
    Yuan A; Yu CJ; Shun CT; Luh KT; Kuo SH; Lee YC; Yang PC
    Int J Cancer; 2005 Jul; 115(4):545-55. PubMed ID: 15704107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
    Kim GY; Lim SJ; Kim YW
    Mod Pathol; 2011 Oct; 24(10):1336-47. PubMed ID: 21572400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.
    Sawabata N; Asamura H; Goya T; Mori M; Nakanishi Y; Eguchi K; Koshiishi Y; Okumura M; Miyaoka E; Fujii Y;
    J Thorac Oncol; 2010 Sep; 5(9):1369-75. PubMed ID: 20683209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
    Laga AC; Zander DS; Cagle PT
    Arch Pathol Lab Med; 2005 Sep; 129(9):1113-7. PubMed ID: 16119982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
    Ibe T; Shimizu K; Nakano T; Kakegawa S; Kamiyoshihara M; Nakajima T; Kaira K; Takeyoshi I
    J Surg Oncol; 2010 Jul; 102(1):11-7. PubMed ID: 20578072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer survival in Norway, 1997-2011: from nihilism to optimism.
    Nilssen Y; Strand TE; Fjellbirkeland L; Bartnes K; Møller B
    Eur Respir J; 2016 Jan; 47(1):275-87. PubMed ID: 26541525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
    Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
    Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cox Regression and Parametric Models: Comparison of How They Determine Factors Influencing Survival of Patients with Non-Small Cell Lung Carcinoma.
    Khaksar E; Askarishahi M; Hekmatimoghaddam S; Vahedian-Ardakani H
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3389-3393. PubMed ID: 29286608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.